Posts

Evidence-of-SARS-CoV2-in-heart-cells

Evidence of SARS-CoV2 in heart cells

While SARS-CoV2 has been previously reported to exist in lung tissue in a 78-year-old patient who died of unexpected cardiac arrest when ready for discharge after COVID-19 hospitalisation, recently the first evidence of SARS-CoV2 infection in heart muscle cells has been reported in a case from Brazil and which is supported by evidence from other reports.

First liquid biopsy for NSCLC to receive FDA approval

The development of new targeted therapies for non-small cell lung cancer (NSCLC) in recent years has changed the standard of care for the later stages of NSCLC in specific population groups.

ESMO-releases-the-first-guideline-on-NGS-testing- in-cancers

ESMO releases the first guideline on NGS testing in cancers

Precision therapies were first approved for cancer in 1998, when trastuzumab was approved for HER2+ breast cancer, opening the door for other targeted therapies such as imatinib for Philadelphia chromosome-positive chronic myelogenous leukaemia.

risk-of-thrombosis-with-sars-cov-2-infection

Risk of thrombosis with SARS-CoV-2 infection

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) in late 2019 has led to a global pandemic.

no-difference-in-kidney-transplantation-outcomes-for-HIV-positive-recipients-regardless-of-donor-HIV-status

No difference in kidney transplantation outcomes for HIV-positive recipients regardless of donor HIV status

Human immunodeficiency virus (HIV) has been transformed into a chronic disease to the successful introduction of antiretroviral therapy (ART), and people living with HIV (PWH) now experience morbidity from other chronic conditions, such as kidney, liver, and heart disease.